Global Premenstrual Syndrome Treatment Market - 2025 -2033
Premenstrual Syndrome Treatment Market Size & Industry Outlook
The global premenstrual syndrome treatment market size reached US$ 1.57 Billion in 2024 from US$ 1.52 Billion in 2023 and is expected to reach US$ 2.20 Billion by 2033, growing at a CAGR of 3.8% during the forecast period 2025-2033. The Premenstrual Syndrome (PMS) treatment market is experiencing steady momentum as growing awareness of women’s health and the rising demand for effective symptom management drive adoption of both prescription and over-the-counter solutions. While hormonal therapies, such as oral contraceptives and estrogen–progestin combinations, remain the most widely used treatment options, there is significant expansion in the use of non-hormonal approaches, including SSRIs, NSAIDs, and nutritional supplements, reflecting a shift toward personalized and accessible care.
The market is also being shaped by the rapid expansion of online pharmacies and telemedicine platforms, which make both prescription and OTC products more accessible to younger and tech-savvy consumers. At the same time, innovation in women’s health is accelerating, with companies like Bayer advancing non-hormonal agents such as elinzanetant in late-stage trials and Pfizer exploring SSRI variants tailored for PMS relief, signaling a strong pipeline for more targeted therapies. Collectively, these factors are broadening treatment choices, improving patient adherence, and reinforcing the market’s long-term growth trajectory.
Key Market Trends & Insights
Drivers-Rising awareness and destigmatization of menstrual health are significantly driving the premenstrual syndrome treatment market growth
The rising awareness and destigmatization of menstrual health are one of the most influential forces driving the growth of the market, as they directly impact diagnosis rates, patient demand, and treatment adoption. Historically, menstruation and related conditions like PMS and PMDD were rarely discussed openly due to cultural taboos, leading to underdiagnosis and self-management with home remedies. However, in recent years, global awareness campaigns by NGOs, governments, and healthcare organizations have helped normalize conversations around menstrual health.
For instance, initiatives like UNESCO’s menstrual hygiene education programs in Asia and Africa, as well as global campaigns like “Period Positive,” have increased knowledge of menstrual-related disorders and encouraged women to seek medical care. Social media has also played a pivotal role, platforms such as Instagram and TikTok have become channels where influencers, healthcare professionals, and advocacy groups spread information about PMS symptoms and available treatments, making the topic more mainstream. This cultural shift is translating into higher patient volumes seeking professional help and consequently expanding the market for prescription drugs like SSRIs and hormonal contraceptives, as well as OTC remedies such as NSAIDs and supplements.
Furthermore, employers and insurers are beginning to recognize PMS as a factor in workplace productivity and absenteeism, leading to its inclusion in wellness programs, a move that further drives treatment uptake. Collectively, these trends show how breaking the stigma and spreading awareness are not only empowering women to seek care but also creating a fertile environment for market expansion across clinical, consumer health, and digital health channels.
Restraints-Side effects and limitations of current therapies are hampering the growth of the premenstrual syndrome treatment market
The side effects and limitations of current therapies are major factors restraining the growth of the market, as they directly affect patient adherence, physician prescribing patterns, and overall market acceptance. Widely used SSRIs such as fluoxetine or sertraline are effective for mood-related PMS and PMDD symptoms but are often associated with side effects, including nausea, insomnia, sexual dysfunction, and weight gain. Many women discontinue these treatments prematurely, reducing long-term demand. Similarly, NSAIDs like ibuprofen and naproxen are first-line options for pain and cramping, but prolonged use carries risks of gastrointestinal bleeding, ulcers, and kidney damage, limiting their suitability for chronic monthly use.
Hormonal contraceptives, another cornerstone therapy, can cause adverse effects such as breakthrough bleeding, headaches, breast tenderness, and, in some cases, an elevated risk of cardiovascular issues, which makes some women reluctant to use them despite their efficacy. For severe cases treated with GnRH analogues, side effects like hot flashes, bone density loss, and high costs further restrict adoption to niche patient groups. In addition, many women perceive conventional medications as too aggressive for what they consider a “natural” monthly condition, prompting them to turn to herbal remedies or lifestyle adjustments instead of pharmacological therapies.
These concerns are compounded in emerging markets, where limited healthcare access and poor awareness of safe usage amplify fears about side effects. For pharmaceutical companies, this translates into slower market penetration, higher discontinuation rates, and greater pressure to develop safer, more tolerable alternatives. This restraint is precisely why non-hormonal innovations like Bayer’s elinzanetant and nutraceutical-based approaches are gaining traction, as they attempt to bridge the gap left by the limitations of existing options.
Premenstrual Syndrome Treatment Market, Segment Analysis
The global premenstrual syndrome treatment market is segmented based on drug type, indication, distribution channel, and region.
Drug Type-The analgesics & NSAIDs segment is dominating the premenstrual syndrome treatment market with a 22.98% share in 2024
The analgesics & NSAIDs segment is the dominant segment in the PMS treatment market, primarily due to its accessibility, affordability, and effectiveness in managing the most common physical symptoms of PMS, such as menstrual cramps, headaches, and joint pain. Most women experiencing mild-to-moderate PMS opt for over-the-counter solutions before seeking prescription therapies, making NSAIDs like ibuprofen, naproxen, and aspirin household staples. Products such as Midol, Advil, and Aleve are widely recognized and used globally, contributing significantly to market volume. The segment’s dominance is further reinforced by the rapid growth of OTC retail channels and e-commerce platforms, which allow easy, discreet access to these medications.
Additionally, NSAIDs offer a fast-acting solution for pain relief without the hormonal side effects associated with oral contraceptives or the psychiatric effects of SSRIs, making them the preferred first-line treatment for a large proportion of women. This high volume usage ensures that analgesics & NSAIDs hold the largest share by user base, even though revenue per patient may be lower compared to prescription therapies. Furthermore, companies continue to innovate within this segment by offering combination products, such as Midol Complete, which pairs NSAIDs with caffeine or vitamins to enhance efficacy, further strengthening market leadership. Overall, the segment’s widespread acceptance, OTC availability, and effectiveness for the majority of PMS sufferers solidify its dominant position in the market.
Geographical Analysis
North America is expected to dominate the global premenstrual syndrome treatment market with a 42.53% in 2024
The North America region dominates the global market due to a combination of high awareness, advanced healthcare infrastructure, and widespread accessibility of both prescription and over-the-counter (OTC) treatments. The region benefits from strong public health initiatives and educational campaigns that have destigmatized menstrual health, encouraging more women to seek treatment for PMS and PMDD. The United States, in particular, leads in the adoption of innovative therapies, supported by regulatory frameworks that facilitate faster approvals and reimbursement for prescription medications. Widely used products such as SSRIs (fluoxetine, sertraline), NSAIDs (ibuprofen, naproxen), and oral contraceptives (Yasmin, Loestrin) are easily available through pharmacies and online platforms, which strengthens patient access and adherence.
OTC brands like Midol, Advil, and Aleve are household names, driving high-volume usage among women with mild-to-moderate PMS symptoms. North America also benefits from a mature digital health ecosystem, with telemedicine platforms enabling remote consultations and home delivery of prescription therapies, making care more convenient, especially for working women and younger demographics. Pharmaceutical companies such as Bayer, Pfizer, Eli Lilly, and other emerging players are actively investing in research and development in this region, introducing novel treatments like Bayer’s non-hormonal elinzanetant and exploring SSRIs tailored for PMDD, which strengthens the pipeline and attracts early adoption.
The Asia Pacific region is the fastest-growing region in the global premenstrual syndrome treatment market in 2024
The Asia-Pacific region is the fastest-growing market for PMS treatments due to rising awareness of women’s health, increasing healthcare access, and a growing acceptance of both prescription and over-the-counter (OTC) therapies. Countries such as India, China, Japan, and South Korea are witnessing a cultural shift toward openly discussing menstrual health, supported by government initiatives, NGO campaigns, and digital health education platforms that encourage women to seek treatment for PMS and PMDD. The large population base, combined with increasing urbanization and disposable income, has expanded access to healthcare facilities, pharmacies, and e-commerce channels, making both NSAIDs and SSRIs more readily available.
Widely used products in the region include NSAIDs like ibuprofen and naproxen (brands such as Advil and Combiflam), SSRIs like fluoxetine and sertraline, and oral contraceptives like Yasmin and Marvelon. OTC nutraceuticals and herbal remedies, including magnesium, vitamin B6, calcium, and chasteberry-based supplements, are also rapidly gaining popularity among health-conscious consumers seeking natural alternatives. The rise of telemedicine and online pharmacy platforms has further accelerated adoption, allowing women in semi-urban and rural areas to access consultation and treatment discreetly.
Pharmaceutical companies are increasingly targeting the Asia-Pacific for product launches and clinical trials due to lower regulatory barriers and the large, untreated population. Additionally, younger demographics, particularly millennials and Gen Z, are more receptive to wellness-focused approaches, digital apps for menstrual tracking, and subscription-based delivery of PMS management products. The combination of increasing awareness, evolving consumer behavior, rising healthcare expenditure, and expanding digital access positions the Asia-Pacific as a high-growth region.
Competitive Landscape
Top companies in the premenstrual syndrome treatment market include Haleon Group, Bayer, Eli Lilly and Company, GSK, Lundbeck A/S, Pfizer Inc, AstraZeneca, Novartis International AG, and MetP Pharma AG , among others.
The global premenstrual syndrome treatment market report delivers a detailed analysis with 59 key tables, more than 54 visually impactful figures, and 159 pages of expert insights, providing a complete view of the market landscape.
The global premenstrual syndrome treatment market size reached US$ 1.57 Billion in 2024 from US$ 1.52 Billion in 2023 and is expected to reach US$ 2.20 Billion by 2033, growing at a CAGR of 3.8% during the forecast period 2025-2033. The Premenstrual Syndrome (PMS) treatment market is experiencing steady momentum as growing awareness of women’s health and the rising demand for effective symptom management drive adoption of both prescription and over-the-counter solutions. While hormonal therapies, such as oral contraceptives and estrogen–progestin combinations, remain the most widely used treatment options, there is significant expansion in the use of non-hormonal approaches, including SSRIs, NSAIDs, and nutritional supplements, reflecting a shift toward personalized and accessible care.
The market is also being shaped by the rapid expansion of online pharmacies and telemedicine platforms, which make both prescription and OTC products more accessible to younger and tech-savvy consumers. At the same time, innovation in women’s health is accelerating, with companies like Bayer advancing non-hormonal agents such as elinzanetant in late-stage trials and Pfizer exploring SSRI variants tailored for PMS relief, signaling a strong pipeline for more targeted therapies. Collectively, these factors are broadening treatment choices, improving patient adherence, and reinforcing the market’s long-term growth trajectory.
Key Market Trends & Insights
- Key trends in the PMS treatment market highlight a shift toward non-hormonal and natural therapies, as consumers increasingly prefer SSRIs, NSAIDs, and supplements like chasteberry, magnesium, and vitamin B6 over long-term hormonal use. The expansion of digital health and online pharmacies is reshaping access, particularly in emerging markets, with e-commerce and telemedicine platforms driving OTC sales and prescription adherence. These dynamics collectively reflect a market that is diversifying, digitalizing, and moving toward more patient-centric and accessible treatment solutions.
- North America dominates the premenstrual syndrome treatment market with the largest revenue share of 42.53% in 2024.
- The Asia Pacific is the fastest-growing region and is expected to grow at the fastest CAGR of 3.7% over the forecast period.
- Based on application, the infectious diseases segment led the market with the largest revenue share of 22.98% in 2024.
- The major market players in the premenstrual syndrome treatment market are Haleon Group, Bayer, Eli Lilly and Company, GSK, Lundbeck A/S, Pfizer Inc., AstraZeneca, Novartis International AG, and MetP Pharma AG, among others
- 2024 Market Size: US$ 1.57 Billion
- 2033 Projected Market Size: US$ 2.20 Billion
- CAGR (2025–2033): 3.8%
- North America: Largest market in 2024
- Asia Pacific: Fastest-growing market
Drivers-Rising awareness and destigmatization of menstrual health are significantly driving the premenstrual syndrome treatment market growth
The rising awareness and destigmatization of menstrual health are one of the most influential forces driving the growth of the market, as they directly impact diagnosis rates, patient demand, and treatment adoption. Historically, menstruation and related conditions like PMS and PMDD were rarely discussed openly due to cultural taboos, leading to underdiagnosis and self-management with home remedies. However, in recent years, global awareness campaigns by NGOs, governments, and healthcare organizations have helped normalize conversations around menstrual health.
For instance, initiatives like UNESCO’s menstrual hygiene education programs in Asia and Africa, as well as global campaigns like “Period Positive,” have increased knowledge of menstrual-related disorders and encouraged women to seek medical care. Social media has also played a pivotal role, platforms such as Instagram and TikTok have become channels where influencers, healthcare professionals, and advocacy groups spread information about PMS symptoms and available treatments, making the topic more mainstream. This cultural shift is translating into higher patient volumes seeking professional help and consequently expanding the market for prescription drugs like SSRIs and hormonal contraceptives, as well as OTC remedies such as NSAIDs and supplements.
Furthermore, employers and insurers are beginning to recognize PMS as a factor in workplace productivity and absenteeism, leading to its inclusion in wellness programs, a move that further drives treatment uptake. Collectively, these trends show how breaking the stigma and spreading awareness are not only empowering women to seek care but also creating a fertile environment for market expansion across clinical, consumer health, and digital health channels.
Restraints-Side effects and limitations of current therapies are hampering the growth of the premenstrual syndrome treatment market
The side effects and limitations of current therapies are major factors restraining the growth of the market, as they directly affect patient adherence, physician prescribing patterns, and overall market acceptance. Widely used SSRIs such as fluoxetine or sertraline are effective for mood-related PMS and PMDD symptoms but are often associated with side effects, including nausea, insomnia, sexual dysfunction, and weight gain. Many women discontinue these treatments prematurely, reducing long-term demand. Similarly, NSAIDs like ibuprofen and naproxen are first-line options for pain and cramping, but prolonged use carries risks of gastrointestinal bleeding, ulcers, and kidney damage, limiting their suitability for chronic monthly use.
Hormonal contraceptives, another cornerstone therapy, can cause adverse effects such as breakthrough bleeding, headaches, breast tenderness, and, in some cases, an elevated risk of cardiovascular issues, which makes some women reluctant to use them despite their efficacy. For severe cases treated with GnRH analogues, side effects like hot flashes, bone density loss, and high costs further restrict adoption to niche patient groups. In addition, many women perceive conventional medications as too aggressive for what they consider a “natural” monthly condition, prompting them to turn to herbal remedies or lifestyle adjustments instead of pharmacological therapies.
These concerns are compounded in emerging markets, where limited healthcare access and poor awareness of safe usage amplify fears about side effects. For pharmaceutical companies, this translates into slower market penetration, higher discontinuation rates, and greater pressure to develop safer, more tolerable alternatives. This restraint is precisely why non-hormonal innovations like Bayer’s elinzanetant and nutraceutical-based approaches are gaining traction, as they attempt to bridge the gap left by the limitations of existing options.
Premenstrual Syndrome Treatment Market, Segment Analysis
The global premenstrual syndrome treatment market is segmented based on drug type, indication, distribution channel, and region.
Drug Type-The analgesics & NSAIDs segment is dominating the premenstrual syndrome treatment market with a 22.98% share in 2024
The analgesics & NSAIDs segment is the dominant segment in the PMS treatment market, primarily due to its accessibility, affordability, and effectiveness in managing the most common physical symptoms of PMS, such as menstrual cramps, headaches, and joint pain. Most women experiencing mild-to-moderate PMS opt for over-the-counter solutions before seeking prescription therapies, making NSAIDs like ibuprofen, naproxen, and aspirin household staples. Products such as Midol, Advil, and Aleve are widely recognized and used globally, contributing significantly to market volume. The segment’s dominance is further reinforced by the rapid growth of OTC retail channels and e-commerce platforms, which allow easy, discreet access to these medications.
Additionally, NSAIDs offer a fast-acting solution for pain relief without the hormonal side effects associated with oral contraceptives or the psychiatric effects of SSRIs, making them the preferred first-line treatment for a large proportion of women. This high volume usage ensures that analgesics & NSAIDs hold the largest share by user base, even though revenue per patient may be lower compared to prescription therapies. Furthermore, companies continue to innovate within this segment by offering combination products, such as Midol Complete, which pairs NSAIDs with caffeine or vitamins to enhance efficacy, further strengthening market leadership. Overall, the segment’s widespread acceptance, OTC availability, and effectiveness for the majority of PMS sufferers solidify its dominant position in the market.
Geographical Analysis
North America is expected to dominate the global premenstrual syndrome treatment market with a 42.53% in 2024
The North America region dominates the global market due to a combination of high awareness, advanced healthcare infrastructure, and widespread accessibility of both prescription and over-the-counter (OTC) treatments. The region benefits from strong public health initiatives and educational campaigns that have destigmatized menstrual health, encouraging more women to seek treatment for PMS and PMDD. The United States, in particular, leads in the adoption of innovative therapies, supported by regulatory frameworks that facilitate faster approvals and reimbursement for prescription medications. Widely used products such as SSRIs (fluoxetine, sertraline), NSAIDs (ibuprofen, naproxen), and oral contraceptives (Yasmin, Loestrin) are easily available through pharmacies and online platforms, which strengthens patient access and adherence.
OTC brands like Midol, Advil, and Aleve are household names, driving high-volume usage among women with mild-to-moderate PMS symptoms. North America also benefits from a mature digital health ecosystem, with telemedicine platforms enabling remote consultations and home delivery of prescription therapies, making care more convenient, especially for working women and younger demographics. Pharmaceutical companies such as Bayer, Pfizer, Eli Lilly, and other emerging players are actively investing in research and development in this region, introducing novel treatments like Bayer’s non-hormonal elinzanetant and exploring SSRIs tailored for PMDD, which strengthens the pipeline and attracts early adoption.
The Asia Pacific region is the fastest-growing region in the global premenstrual syndrome treatment market in 2024
The Asia-Pacific region is the fastest-growing market for PMS treatments due to rising awareness of women’s health, increasing healthcare access, and a growing acceptance of both prescription and over-the-counter (OTC) therapies. Countries such as India, China, Japan, and South Korea are witnessing a cultural shift toward openly discussing menstrual health, supported by government initiatives, NGO campaigns, and digital health education platforms that encourage women to seek treatment for PMS and PMDD. The large population base, combined with increasing urbanization and disposable income, has expanded access to healthcare facilities, pharmacies, and e-commerce channels, making both NSAIDs and SSRIs more readily available.
Widely used products in the region include NSAIDs like ibuprofen and naproxen (brands such as Advil and Combiflam), SSRIs like fluoxetine and sertraline, and oral contraceptives like Yasmin and Marvelon. OTC nutraceuticals and herbal remedies, including magnesium, vitamin B6, calcium, and chasteberry-based supplements, are also rapidly gaining popularity among health-conscious consumers seeking natural alternatives. The rise of telemedicine and online pharmacy platforms has further accelerated adoption, allowing women in semi-urban and rural areas to access consultation and treatment discreetly.
Pharmaceutical companies are increasingly targeting the Asia-Pacific for product launches and clinical trials due to lower regulatory barriers and the large, untreated population. Additionally, younger demographics, particularly millennials and Gen Z, are more receptive to wellness-focused approaches, digital apps for menstrual tracking, and subscription-based delivery of PMS management products. The combination of increasing awareness, evolving consumer behavior, rising healthcare expenditure, and expanding digital access positions the Asia-Pacific as a high-growth region.
Competitive Landscape
Top companies in the premenstrual syndrome treatment market include Haleon Group, Bayer, Eli Lilly and Company, GSK, Lundbeck A/S, Pfizer Inc, AstraZeneca, Novartis International AG, and MetP Pharma AG , among others.
The global premenstrual syndrome treatment market report delivers a detailed analysis with 59 key tables, more than 54 visually impactful figures, and 159 pages of expert insights, providing a complete view of the market landscape.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Drug Type
2.4. Snippet by Indication
2.5. Snippet by Distribution Channel
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Awareness and Destigmatization of Menstrual Health
3.1.1.2. Innovation in Safer and Non-hormonal Therapies
3.1.2. Restraints
3.1.2.1. Side Effects and Limitations of Current Therapies
3.1.2.2. Underdiagnosis and Cultural Stigma
3.1.3. Opportunity
3.1.3.1. Expansion of Non-hormonal and Targeted Therapies
3.1.3.2. Digital Health Integration and Telemedicine
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Patent Analysis
4.6. Unmet Needs and Gaps
4.7. Recommended Strategies for Market Entry and Expansion
4.8. Pricing Analysis and Price Dynamics
5. BY DRUG TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
5.1.2. Market Attractiveness Index, By Drug Type
5.2. Analgesics & NSAIDs*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Antidepressants
5.4. Oral Contraceptives
5.5. Ovarian Suppression Agents
5.6. Gonadotropin-Releasing Hormone (GnRH) Analogues
5.7. Selective Serotonin Reuptake Inhibitors (SSRIs)
5.8. Others
6. BY INDICATION
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
6.1.2. Market Attractiveness Index, By Indication
6.2. Mild-to-Moderate PMS *
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Severe PMS
7. BY DISTRIBUTION CHANNEL
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
7.1.2. Market Attractiveness Index, By Distribution Channel
7.2. Hospital Pharmacies*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Drug Stores & Retail Pharmacies
7.4. Online Pharmacies
8. BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. UK
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. Asia-Pacific
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. China
8.4.6.2. India
8.4.6.3. Japan
8.4.6.4. South Korea
8.4.6.5. Rest of Asia-Pacific
8.4.7. South America
8.4.7.1. Introduction
8.4.7.2. Key Region-Specific Dynamics
8.4.7.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.4.7.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.4.7.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.4.7.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.7.6.1. Brazil
8.4.7.6.2. Argentina
8.4.7.6.3. Rest of South America
8.5. Middle East and Africa
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
10.1. Haleon Group*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.3. Financial Overview
10.1.3.1. Company Revenue
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.4.4. SWOT Analysis
10.2. Bayer
10.3. Eli Lilly And Company
10.4. GSK
10.5. Lundbeck A/S
10.6. Pfizer Inc
10.7. AstraZeneca
10.8. Novartis International AG
10.9. MetP Pharma AG (LIST NOT EXHAUSTIVE)
11. ASSUMPTIONS AND RESEARCH METHODOLOGY
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Drug Type
2.4. Snippet by Indication
2.5. Snippet by Distribution Channel
2.6. Snippet by Region
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Awareness and Destigmatization of Menstrual Health
3.1.1.2. Innovation in Safer and Non-hormonal Therapies
3.1.2. Restraints
3.1.2.1. Side Effects and Limitations of Current Therapies
3.1.2.2. Underdiagnosis and Cultural Stigma
3.1.3. Opportunity
3.1.3.1. Expansion of Non-hormonal and Targeted Therapies
3.1.3.2. Digital Health Integration and Telemedicine
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with the Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
4.3.1. North America
4.3.2. Europe
4.3.3. Asia Pacific
4.3.4. South America
4.3.5. Middle East & Africa
4.4. Porter’s Five Forces Analysis
4.5. Patent Analysis
4.6. Unmet Needs and Gaps
4.7. Recommended Strategies for Market Entry and Expansion
4.8. Pricing Analysis and Price Dynamics
5. BY DRUG TYPE
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
5.1.2. Market Attractiveness Index, By Drug Type
5.2. Analgesics & NSAIDs*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Antidepressants
5.4. Oral Contraceptives
5.5. Ovarian Suppression Agents
5.6. Gonadotropin-Releasing Hormone (GnRH) Analogues
5.7. Selective Serotonin Reuptake Inhibitors (SSRIs)
5.8. Others
6. BY INDICATION
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
6.1.2. Market Attractiveness Index, By Indication
6.2. Mild-to-Moderate PMS *
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Severe PMS
7. BY DISTRIBUTION CHANNEL
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
7.1.2. Market Attractiveness Index, By Distribution Channel
7.2. Hospital Pharmacies*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Drug Stores & Retail Pharmacies
7.4. Online Pharmacies
8. BY REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
8.1.2. Market Attractiveness Index, By Region
8.2. North America
8.2.1. Introduction
8.2.2. Key Region-Specific Dynamics
8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.2.6.1. U.S.
8.2.6.2. Canada
8.2.6.3. Mexico
8.3. Europe
8.3.1. Introduction
8.3.2. Key Region-Specific Dynamics
8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.3.6.1. Germany
8.3.6.2. UK
8.3.6.3. France
8.3.6.4. Spain
8.3.6.5. Italy
8.3.6.6. Rest of Europe
8.4. Asia-Pacific
8.4.1. Introduction
8.4.2. Key Region-Specific Dynamics
8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.6.1. China
8.4.6.2. India
8.4.6.3. Japan
8.4.6.4. South Korea
8.4.6.5. Rest of Asia-Pacific
8.4.7. South America
8.4.7.1. Introduction
8.4.7.2. Key Region-Specific Dynamics
8.4.7.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.4.7.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.4.7.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
8.4.7.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
8.4.7.6.1. Brazil
8.4.7.6.2. Argentina
8.4.7.6.3. Rest of South America
8.5. Middle East and Africa
8.5.1. Introduction
8.5.2. Key Region-Specific Dynamics
8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
10.1. Haleon Group*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.3. Financial Overview
10.1.3.1. Company Revenue
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.4.4. SWOT Analysis
10.2. Bayer
10.3. Eli Lilly And Company
10.4. GSK
10.5. Lundbeck A/S
10.6. Pfizer Inc
10.7. AstraZeneca
10.8. Novartis International AG
10.9. MetP Pharma AG (LIST NOT EXHAUSTIVE)
11. ASSUMPTIONS AND RESEARCH METHODOLOGY
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
LIST OF TABLES
Table 1 Global Premenstrual Syndrome Treatment Market Value, By Drug Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Premenstrual Syndrome Treatment Market Value, By Indication, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Premenstrual Syndrome Treatment Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Premenstrual Syndrome Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Premenstrual Syndrome Treatment Market Value, By Drug Type, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Premenstrual Syndrome Treatment Market Value, By Drug Type, 2022-2033 (US$ Billion)
Table 7 Global Premenstrual Syndrome Treatment Market Value, By Indication, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Premenstrual Syndrome Treatment Market Value, By Indication, 2022-2033 (US$ Billion)
Table 9 Global Premenstrual Syndrome Treatment Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global Premenstrual Syndrome Treatment Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 11 Global Premenstrual Syndrome Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global Premenstrual Syndrome Treatment Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America Premenstrual Syndrome Treatment Market Value, By Drug Type, 2022-2033 (US$ Billion)
Table 14 North America Premenstrual Syndrome Treatment Market Value, By Indication, 2022-2033 (US$ Billion)
Table 15 North America Premenstrual Syndrome Treatment Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 16 North America Premenstrual Syndrome Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 Europe Premenstrual Syndrome Treatment Market Value, By Drug Type, 2022-2033 (US$ Billion)
Table 18 Europe Premenstrual Syndrome Treatment Market Value, By Indication, 2022-2033 (US$ Billion)
Table 19 Europe Premenstrual Syndrome Treatment Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 20 Europe Premenstrual Syndrome Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific Premenstrual Syndrome Treatment Market Value, By Drug Type, 2022-2033 (US$ Billion)
Table 22 Asia-Pacific Premenstrual Syndrome Treatment Market Value, By Indication, 2022-2033 (US$ Billion)
Table 23 Asia-Pacific Premenstrual Syndrome Treatment Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 24 Asia-Pacific Premenstrual Syndrome Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 South America Premenstrual Syndrome Treatment Market Value, By Drug Type, 2022-2033 (US$ Billion)
Table 26 South America Premenstrual Syndrome Treatment Market Value, By Indication, 2022-2033 (US$ Billion)
Table 27 South America Premenstrual Syndrome Treatment Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 28 South America Premenstrual Syndrome Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa Premenstrual Syndrome Treatment Market Value, By Drug Type, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa Premenstrual Syndrome Treatment Market Value, By Indication, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa Premenstrual Syndrome Treatment Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 32 Middle East and Africa Premenstrual Syndrome Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 Haleon Group: Overview
Table 34 Haleon Group: Product Portfolio
Table 35 Haleon Group: Key Developments
Table 36 Bayer: Overview
Table 37 Bayer: Product Portfolio
Table 38 Bayer: Key Developments
Table 39 Eli Lilly And Company: Overview
Table 40 Eli Lilly And Company: Product Portfolio
Table 41 Eli Lilly And Company: Key Developments
Table 42 GSK: Overview
Table 43 GSK: Product Portfolio
Table 44 GSK: Key Developments
Table 45 Lundbeck A/S: Overview
Table 46 Lundbeck A/S: Product Portfolio
Table 47 Lundbeck A/S: Key Developments
Table 48 Pfizer Inc: Overview
Table 49 Pfizer Inc: Product Portfolio
Table 50 Pfizer Inc: Key Developments
Table 51 AstraZeneca: Overview
Table 52 AstraZeneca: Product Portfolio
Table 53 AstraZeneca: Key Developments
Table 54 Novartis International AG: Overview
Table 55 Novartis International AG: Product Portfolio
Table 56 Novartis International AG: Key Developments
Table 57 MetP Pharma AG: Overview
Table 58 MetP Pharma AG: Product Portfolio
Table 59 MetP Pharma AG: Key Developments
Table 1 Global Premenstrual Syndrome Treatment Market Value, By Drug Type, 2025, 2029 & 2033 (US$ Billion)
Table 2 Global Premenstrual Syndrome Treatment Market Value, By Indication, 2025, 2029 & 2033 (US$ Billion)
Table 3 Global Premenstrual Syndrome Treatment Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 4 Global Premenstrual Syndrome Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 5 Global Premenstrual Syndrome Treatment Market Value, By Drug Type, 2025, 2029 & 2033 (US$ Billion)
Table 6 Global Premenstrual Syndrome Treatment Market Value, By Drug Type, 2022-2033 (US$ Billion)
Table 7 Global Premenstrual Syndrome Treatment Market Value, By Indication, 2025, 2029 & 2033 (US$ Billion)
Table 8 Global Premenstrual Syndrome Treatment Market Value, By Indication, 2022-2033 (US$ Billion)
Table 9 Global Premenstrual Syndrome Treatment Market Value, By Distribution Channel, 2025, 2029 & 2033 (US$ Billion)
Table 10 Global Premenstrual Syndrome Treatment Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 11 Global Premenstrual Syndrome Treatment Market Value, By Region, 2025, 2029 & 2033 (US$ Billion)
Table 12 Global Premenstrual Syndrome Treatment Market Value, By Region, 2022-2033 (US$ Billion)
Table 13 North America Premenstrual Syndrome Treatment Market Value, By Drug Type, 2022-2033 (US$ Billion)
Table 14 North America Premenstrual Syndrome Treatment Market Value, By Indication, 2022-2033 (US$ Billion)
Table 15 North America Premenstrual Syndrome Treatment Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 16 North America Premenstrual Syndrome Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 17 Europe Premenstrual Syndrome Treatment Market Value, By Drug Type, 2022-2033 (US$ Billion)
Table 18 Europe Premenstrual Syndrome Treatment Market Value, By Indication, 2022-2033 (US$ Billion)
Table 19 Europe Premenstrual Syndrome Treatment Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 20 Europe Premenstrual Syndrome Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 21 Asia-Pacific Premenstrual Syndrome Treatment Market Value, By Drug Type, 2022-2033 (US$ Billion)
Table 22 Asia-Pacific Premenstrual Syndrome Treatment Market Value, By Indication, 2022-2033 (US$ Billion)
Table 23 Asia-Pacific Premenstrual Syndrome Treatment Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 24 Asia-Pacific Premenstrual Syndrome Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 25 South America Premenstrual Syndrome Treatment Market Value, By Drug Type, 2022-2033 (US$ Billion)
Table 26 South America Premenstrual Syndrome Treatment Market Value, By Indication, 2022-2033 (US$ Billion)
Table 27 South America Premenstrual Syndrome Treatment Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 28 South America Premenstrual Syndrome Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 29 Middle East and Africa Premenstrual Syndrome Treatment Market Value, By Drug Type, 2022-2033 (US$ Billion)
Table 30 Middle East and Africa Premenstrual Syndrome Treatment Market Value, By Indication, 2022-2033 (US$ Billion)
Table 31 Middle East and Africa Premenstrual Syndrome Treatment Market Value, By Distribution Channel, 2022-2033 (US$ Billion)
Table 32 Middle East and Africa Premenstrual Syndrome Treatment Market Value, By Country, 2022-2033 (US$ Billion)
Table 33 Haleon Group: Overview
Table 34 Haleon Group: Product Portfolio
Table 35 Haleon Group: Key Developments
Table 36 Bayer: Overview
Table 37 Bayer: Product Portfolio
Table 38 Bayer: Key Developments
Table 39 Eli Lilly And Company: Overview
Table 40 Eli Lilly And Company: Product Portfolio
Table 41 Eli Lilly And Company: Key Developments
Table 42 GSK: Overview
Table 43 GSK: Product Portfolio
Table 44 GSK: Key Developments
Table 45 Lundbeck A/S: Overview
Table 46 Lundbeck A/S: Product Portfolio
Table 47 Lundbeck A/S: Key Developments
Table 48 Pfizer Inc: Overview
Table 49 Pfizer Inc: Product Portfolio
Table 50 Pfizer Inc: Key Developments
Table 51 AstraZeneca: Overview
Table 52 AstraZeneca: Product Portfolio
Table 53 AstraZeneca: Key Developments
Table 54 Novartis International AG: Overview
Table 55 Novartis International AG: Product Portfolio
Table 56 Novartis International AG: Key Developments
Table 57 MetP Pharma AG: Overview
Table 58 MetP Pharma AG: Product Portfolio
Table 59 MetP Pharma AG: Key Developments
LIST OF FIGURES
Figure 1 Global Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Premenstrual Syndrome Treatment Market Share, By Drug Type, 2024 & 2033 (%)
Figure 3 Global Premenstrual Syndrome Treatment Market Share, By Indication, 2024 & 2033 (%)
Figure 4 Global Premenstrual Syndrome Treatment Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 5 Global Premenstrual Syndrome Treatment Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global Premenstrual Syndrome Treatment Market Y-o-Y Growth, By Drug Type, 2023-2033 (%)
Figure 7 Analgesics & NSAIDs Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 8 Antidepressants Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 9 Oral Contraceptives Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 10 Ovarian Suppression Agents Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 11 Gonadotropin-Releasing Hormone (GnRH) Analogues Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 12 Selective Serotonin Reuptake Inhibitors (SSRIs) Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 13 Others Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 14 Global Premenstrual Syndrome Treatment Market Y-o-Y Growth, By Indication, 2023-2033 (%)
Figure 15 Mild-to-Moderate PMS Indication in Global Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 16 Severe PMS Indication in Global Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 17 Global Premenstrual Syndrome Treatment Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)
Figure 18 Hospital Pharmacies Distribution Channel in Global Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 19 Drug Stores & Retail Pharmacies Distribution Channel in Global Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 20 Online Pharmacies Distribution Channel in Global Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 21 Global Premenstrual Syndrome Treatment Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 22 North America Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 23 North America Premenstrual Syndrome Treatment Market Share, By Drug Type, 2024 & 2033 (%)
Figure 24 North America Premenstrual Syndrome Treatment Market Share, By Indication, 2024 & 2033 (%)
Figure 25 North America Premenstrual Syndrome Treatment Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 26 North America Premenstrual Syndrome Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 27 Europe Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 28 Europe Premenstrual Syndrome Treatment Market Share, By Drug Type, 2024 & 2033 (%)
Figure 29 Europe Premenstrual Syndrome Treatment Market Share, By Indication, 2024 & 2033 (%)
Figure 30 Europe Premenstrual Syndrome Treatment Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 31 Europe Premenstrual Syndrome Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 32 Asia-Pacific Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 33 Asia-Pacific Premenstrual Syndrome Treatment Market Share, By Drug Type, 2024 & 2033 (%)
Figure 34 Asia-Pacific Premenstrual Syndrome Treatment Market Share, By Indication, 2024 & 2033 (%)
Figure 35 Asia-Pacific Premenstrual Syndrome Treatment Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 36 Asia-Pacific Premenstrual Syndrome Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 37 South America Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 38 South America Premenstrual Syndrome Treatment Market Share, By Drug Type, 2024 & 2033 (%)
Figure 39 South America Premenstrual Syndrome Treatment Market Share, By Indication, 2024 & 2033 (%)
Figure 40 South America Premenstrual Syndrome Treatment Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 41 South America Premenstrual Syndrome Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 42 Middle East and Africa Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 43 Middle East and Africa Premenstrual Syndrome Treatment Market Share, By Drug Type, 2024 & 2033 (%)
Figure 44 Middle East and Africa Premenstrual Syndrome Treatment Market Share, By Indication, 2024 & 2033 (%)
Figure 45 Middle East and Africa Premenstrual Syndrome Treatment Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 46 Haleon Group: Financials
Figure 47 Bayer: Financials
Figure 48 Eli Lilly And Company: Financials
Figure 49 GSK: Financials
Figure 50 Lundbeck A/S: Financials
Figure 51 Pfizer Inc: Financials
Figure 52 AstraZeneca: Financials
Figure 53 Novartis International AG: Financials
Figure 54 MetP Pharma AG: Financials
Figure 1 Global Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 2 Global Premenstrual Syndrome Treatment Market Share, By Drug Type, 2024 & 2033 (%)
Figure 3 Global Premenstrual Syndrome Treatment Market Share, By Indication, 2024 & 2033 (%)
Figure 4 Global Premenstrual Syndrome Treatment Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 5 Global Premenstrual Syndrome Treatment Market Share, By Region, 2024 & 2033 (%)
Figure 6 Global Premenstrual Syndrome Treatment Market Y-o-Y Growth, By Drug Type, 2023-2033 (%)
Figure 7 Analgesics & NSAIDs Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 8 Antidepressants Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 9 Oral Contraceptives Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 10 Ovarian Suppression Agents Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 11 Gonadotropin-Releasing Hormone (GnRH) Analogues Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 12 Selective Serotonin Reuptake Inhibitors (SSRIs) Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 13 Others Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 14 Global Premenstrual Syndrome Treatment Market Y-o-Y Growth, By Indication, 2023-2033 (%)
Figure 15 Mild-to-Moderate PMS Indication in Global Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 16 Severe PMS Indication in Global Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 17 Global Premenstrual Syndrome Treatment Market Y-o-Y Growth, By Distribution Channel, 2023-2033 (%)
Figure 18 Hospital Pharmacies Distribution Channel in Global Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 19 Drug Stores & Retail Pharmacies Distribution Channel in Global Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 20 Online Pharmacies Distribution Channel in Global Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 21 Global Premenstrual Syndrome Treatment Market Y-o-Y Growth, By Region, 2023-2033 (%)
Figure 22 North America Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 23 North America Premenstrual Syndrome Treatment Market Share, By Drug Type, 2024 & 2033 (%)
Figure 24 North America Premenstrual Syndrome Treatment Market Share, By Indication, 2024 & 2033 (%)
Figure 25 North America Premenstrual Syndrome Treatment Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 26 North America Premenstrual Syndrome Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 27 Europe Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 28 Europe Premenstrual Syndrome Treatment Market Share, By Drug Type, 2024 & 2033 (%)
Figure 29 Europe Premenstrual Syndrome Treatment Market Share, By Indication, 2024 & 2033 (%)
Figure 30 Europe Premenstrual Syndrome Treatment Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 31 Europe Premenstrual Syndrome Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 32 Asia-Pacific Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 33 Asia-Pacific Premenstrual Syndrome Treatment Market Share, By Drug Type, 2024 & 2033 (%)
Figure 34 Asia-Pacific Premenstrual Syndrome Treatment Market Share, By Indication, 2024 & 2033 (%)
Figure 35 Asia-Pacific Premenstrual Syndrome Treatment Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 36 Asia-Pacific Premenstrual Syndrome Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 37 South America Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 38 South America Premenstrual Syndrome Treatment Market Share, By Drug Type, 2024 & 2033 (%)
Figure 39 South America Premenstrual Syndrome Treatment Market Share, By Indication, 2024 & 2033 (%)
Figure 40 South America Premenstrual Syndrome Treatment Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 41 South America Premenstrual Syndrome Treatment Market Share, By Country, 2024 & 2033 (%)
Figure 42 Middle East and Africa Premenstrual Syndrome Treatment Market Value, 2022-2033 (US$ Billion)
Figure 43 Middle East and Africa Premenstrual Syndrome Treatment Market Share, By Drug Type, 2024 & 2033 (%)
Figure 44 Middle East and Africa Premenstrual Syndrome Treatment Market Share, By Indication, 2024 & 2033 (%)
Figure 45 Middle East and Africa Premenstrual Syndrome Treatment Market Share, By Distribution Channel, 2024 & 2033 (%)
Figure 46 Haleon Group: Financials
Figure 47 Bayer: Financials
Figure 48 Eli Lilly And Company: Financials
Figure 49 GSK: Financials
Figure 50 Lundbeck A/S: Financials
Figure 51 Pfizer Inc: Financials
Figure 52 AstraZeneca: Financials
Figure 53 Novartis International AG: Financials
Figure 54 MetP Pharma AG: Financials
